During the previous grant cycle we undertook the determination of whether microvascular cells from skin possessed unique characteristics, capabilities, and functional properties that would provide insights into the role of endothelial cells in cutaneous homeostasis and pathology. We reasoned that since pathologic and indeed most physiologic events take place at the level of the microvasculature, cells derived from this source would be the most appropriate to study regarding organ specific responsiveness. Inherent in this approach was our hypothesis that not all endothelial cells are alike and that the information derived from studies of large vessel endothelial cells would not be necessarily applicable to microvascular endothelial cells. At that time, and even now, almost all laboratories engaged in the study of endothelial cells used large vessel endothelial cells derived from human umbilical veins, because of the relative ease of isolating and culturing these cells. Conversely, microvascular cells are relatively difficult to isolate and propagate, and their culture requirements are very expensive. We have clearly determined that microvascular endothelial cells from skin differ profoundly from HUVEC in a variety of ways, including growth requirements, state of differentiation, expression of cell adhesion molecules, regulation of cell adhesion molecules at the biochemical and molecular levels, and function of cell adhesion molecules as they relate to cell-cell and cell-matrix interactions. In this next grant cycle, we have chosen to pursue in greater detail three important observations that we have made that are biologically significant and apparently unique to microvascular endothelial cells. These observations involve the microvascular-specific regulated expression of vascular cell adhesion molecule-1 (VCAM1), a cell adhesion molecule fundamentally involved in leukocyte trafficking and localization of immune and inflammatory responses; CD36, a cell surface glycoprotein critically involved in pathologic vaso-occlusive processes within the microvasculature; and TNF-alpha and IL-1, two essential pro- inflammatory cytokines implicated in the initiation and localization of cutaneous inflammation and hypoxic damage. Our studies indicate that the induction and expression profiles of these important proteins are uniquely different in HDMEC, and that these differences are critically important in the pathogenesis of localized inflammatory processes and vaso-occlusive events which occur within the microvascular bed. Therefore, the Specific Aims of this project are: l) To characterize at the molecular, biochemical, and functional levels the regulation of VCAM-1 on HDMEC; 2) To delineate the biochemical, binding, and molecular regulatory characteristics of the HDMEC CD36, and compare these characteristics to those of CD36 described in other tissues; and 3) To determine the conditions and mechanisms by which TNF-alpha, IL-1alpha, and IL-1beta are synthesized and released by HDMEC.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR039632-07
Application #
2079629
Study Section
General Medicine A Subcommittee 2 (GMA)
Project Start
1989-01-01
Project End
1997-12-31
Budget Start
1995-01-01
Budget End
1995-12-31
Support Year
7
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Emory University
Department
Dermatology
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Gira, Amy K; Kowalczyk, Andrew P; Feng, Yue et al. (2009) Iron chelators and hypoxia mimetics inhibit IFNgamma-mediated Jak-STAT signaling. J Invest Dermatol 129:723-9
O'Reilly, Fiona M; Casper, Katherine A; Otto, Kristen B et al. (2003) Regulation of tissue factor in microvascular dermal endothelial cells. J Invest Dermatol 120:489-94
Gira, Amy K; Casper, Katherine A; Otto, Kristen B et al. (2003) Induction of interferon regulatory factor 1 expression in human dermal endothelial cells by interferon-gamma and tumor necrosis factor-alpha is transcriptionally regulated and requires iron. J Invest Dermatol 121:1191-6
Koo, Sang-Wahn; Casper, Katherine A; Otto, Kristen B et al. (2003) Iron chelators inhibit VCAM-1 expression in human dermal microvascular endothelial cells. J Invest Dermatol 120:871-9
Gille, J; Paxton, L L; Lawley, T J et al. (1997) Retinoic acid inhibits the regulated expression of vascular cell adhesion molecule-1 by cultured dermal microvascular endothelial cells. J Clin Invest 99:492-500
Gille, J; Swerlick, R A; Lawley, T J et al. (1996) Differential regulation of vascular cell adhesion molecule-1 gene transcription by tumor necrosis factor alpha and interleukin-1 alpha in dermal microvascular endothelial cells. Blood 87:211-7
Xu, Y; Swerlick, R A; Sepp, N et al. (1994) Characterization of expression and modulation of cell adhesion molecules on an immortalized human dermal microvascular endothelial cell line (HMEC-1). J Invest Dermatol 102:833-7
Swerlick, R A; Lee, K H; Wick, T M et al. (1992) Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol 148:78-83